Injectable electronic chips may revolutionize brain disease treatment with non-surgical approach

• What happened: MIT researchers have unveiled a new approach using microscopic injectable electronic chips to diagnose and treat brain disorders without surgery.

• Why it matters now: This could offer a safer, less invasive alternative to current brain implants and electrode procedures.

• What changes for people: Patients with conditions like Alzheimer’s, chronic pain, and tumors may soon have access to less risky treatment options.

• Who is affected: Patients with neurological disorders, clinicians, and the broader medical technology sector.

A team at the Massachusetts Institute of Technology (MIT) has developed a pioneering technology that uses tiny, injectable electronic chips to reach hard-to-access brain regions without conventional surgery. This innovation holds the potential to transform care for neurological diseases that currently rely on invasive implants.

Instead of drilling into the skull or placing rigid electrodes in the brain, the new method employs microscopic wireless electronic devices that travel through the bloodstream and activate deep inside the brain using external infrared light.

What the technology does

The new system, known as Circulatronics, uses SWEDSs—Soft, Wireless, Electronic Diagnostic and Stimulation units—that are smaller than a single grain of rice. Once injected into the bloodstream, these chips naturally circulate until they reach target sites in the brain.

The devices attach themselves to living tissue without the need for surgical placement. Researchers can then power and control them from outside the skull using infrared laser activation, enabling precise electrical stimulation to support or regulate neural activity.

Why this matters

Traditional treatments for many brain disorders involve invasive procedures that carry risks such as infection, bleeding, and long recovery times. By contrast, a non-surgical approach could reduce procedural risk and extend treatment access to patients who are not candidates for surgery.

Experts say the ability to diagnose and deliver therapy from within the bloodstream opens new possibilities for treating a wide range of conditions, including:

• Alzheimer’s disease
• Chronic neuropathic pain
• Deep-seated brain tumors

If validated in human trials, this method may reshape standards of care in neurology.

Background on the scientist behind the innovation

The lead researcher is Dr. Deblina Sarkar, an Indian-born electrical engineer and inventor raised in Kolkata. She is an assistant professor at MIT and holds advanced degrees in nanoelectronics, including a master’s and PhD from the University of California. Dr. Sarkar earlier founded research exploring biological integration with electronics, and Circulatronics is her latest breakthrough in bridging engineering and medicine.

Her work reflects broader trends in bioelectronics, a field exploring how electronic systems interact with biological tissues to diagnose and treat disease. Experts say such interdisciplinary advances are critical as medicine moves toward personalized and minimally invasive therapies.

Potential implications and next steps

While the concept shows promise, peer-reviewed clinical data are still needed to determine long-term safety and effectiveness. Researchers cited in the field note that injecting functional electronics into living systems poses challenges, including:

• Achieving reliable wireless power transfer
• Ensuring biocompatibility over time
• Preventing immune response or rejection

Early testing and animal studies are key next steps before human trials can begin. Regulatory frameworks may also evolve to accommodate hybrid technologies that sit between conventional medical devices and biologically integrated systems.

Broader context

The innovation comes at a time when global research is intensifying on non-invasive neuromodulation and targeted therapies for neurological conditions. With aging populations facing rising burdens from diseases such as Alzheimer’s and Parkinson’s, there is increasing demand for treatments that reduce risk while improving outcomes.